Total Analytical Error in Validation of Analytical Procedures of Pharmaceuticals
This paper demonstrates how assay data sets of a formulated liquid product, drug substance, and an impurity, obtained from combined accuracy-precision studies, are evaluated to calculate statistical intervals (prediction and tolerance intervals) and to graphically display the total analytical error (TAE) to account for the systematic and random errors.
max_776/Stock.adobe.com
Abstract
This paper demonstrates how assay data sets of a formulated liquid product, drug substance, and an impurity, obtained from combined accuracy-precision studies, are evaluated to calculate statistical intervals (prediction and tolerance intervals) and to graphically display the total analytical error (TAE) to account for the systematic and random errors. Inclusion of either the statistical intervals or the TAE within the allowed accuracy limits is an indication of a successful validation of the accuracy and precision method characteristics. This paper subsequently evaluates the capability of common procedures of pharmaceutical analysis to accommodate acceptable TAE and statistical intervals. While considering typical values of standard deviations (0.5–2.5% relative standard deviation) of chromatographic tests and typical specifications (±2, ±5, or ±10%) of pharmaceuticals, it is shown that a substantial portion of specification tolerance is taken up by either the statistical intervals or by the TAE, particularly in cases of narrow specifications and imprecise procedures.
Peer-Reviewed
Submitted: February 20, 2023
Accepted: March 9, 2023
Click here to read the articleAbout the author
Raphael Bar, is a Consultant at BR Consulting, Israel, rbar@netvision.net.il
Article details
Pharmaceutical Technology
Vol. 47, No. 5
May 2023
Pages: 32–41, 45
Citation
When referring to this article, please cite it as Bar, R. Total Analytical Error in Validation of Analytical Procedures of Pharmaceuticals. Pharmaceutical Technology 2023 47 (5).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
